PACLITAXEL, CISPLATIN AND METHOTREXATE COMBINATION CHEMOTHERAPY IS ACTIVE IN THE TREATMENT OF REFRACTORY UROTHELIAL MALIGNANCIES

Purpose: We investigated the activity of combination chemotherapy cons isting of paclitaxel, cisplatin and methotrexate in patients with adva nced urothelial cancers. Materials and Methods: A total of 25 consecut ive patients with metastatic refractory urothelial malignancies was tr eated with a combination of 200 mg./m.(2) paclitaxel, 30 mg./m.(2) met hotrexate and 70 mg./m.(2) cisplatin in a pilot study. Results: There were no complete responses. Of 25 patients 10 (40%), including 3 of 7 with liver metastases, had a partial response. Hematological and nonhe matological toxicity was tolerable. Conclusions: The combination chemo therapeutic regimen of paclitaxel, cisplatin and methotrexate is activ e in patients with advanced urothelial cancer and warrants further stu dy.